-
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
-
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
-
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
-
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
-
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
-
BioNxt signs commercialization agreement for cladribine drug in Eurasia
-
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
-
BioNxt Announces Closing of Shares for Debt Settlement
-
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
-
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
-
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
-
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
-
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
-
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
-
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
-
BioNxt signs agreement to acquire sublingual drug formulation IP
-
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
-
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
-
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly The
-
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
-
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
-
BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
-
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
-
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
-
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
-
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
-
BioNxt Announces Shares for Debt Settlement
-
BioNxt Solutions Completes Up-Listing to The OTCQB Market
-
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
-
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
-
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
Highlighted Articles
